Current - 6 hours ago
Grey lines are ignored Blue lines are triggers
|
Toggle navigation
* About
* Team
* Portfolio
* News
* Contact
Portfolio
Aisling Capital invests in products, technologies and businesses that advance health.
In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry.
Portfolio Companies
* All
* Sector
+ Biopharma
+ Consumer
+ Diagnostics
+ Medical Device
+ Services
* Geographic Area
+ Ex-US
+ Mid-Atlantic
+ Midwest
+ Mountain
+ New England
+ South
+ West Coast
* Status
+ Current
+ Historic
* Aclaris Therapeutics, Inc.
NasdaqGS: ACRS
Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology.
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Malvern, PA
+ Website
https://aclaristx.com/
* Adams Respiratory Therapeutics, Inc.
Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders
+ Year Invested
2001
+ Fund
I
+ Sector
Consumer
+ Company Status
acquired
+ Investment Status
historic
+ Location
Chester, NJ
+ Website
https://rb.com/
* ADMA Biologics, Inc.
NasdaqCM:ADMA
Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases
+ Year Invested
2007
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Ramsey, NJ
+ Website
https://admabiologics.com/
* Advion, Inc.
Provider of bioanalytical testing equipment to the pharmaceutical industry
+ Year Invested
2002
+ Fund
I
+ Sector
Services
+ Company Status
private
+ Investment Status
historic
+ Location
Ithaca, NY
+ Website
https://advion.com/
* Aeglea BioTherapeutics, Inc.
NasdaqGM:AGLE
Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Austin, TX
+ Website
https://aegleabio.com/
* Agile Therapeutics, Inc.
NasdaqGM:AGRX
Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products
+ Year Invested
2012
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Princeton, NJ
+ Website
https://agiletherapeutics.com/
* Aimmune Therapeutics, Inc.
NasdaqGS:AIMT
Biopharmaceutical company developing desensitization treatments for food allergies
+ Year Invested
2015
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Brisbane, CA
+ Website
https://aimmune.com/
* Ajax Health
Medical device platform building a diversified portfolio of emerging medical device companies
+ Year Invested
2017
+ Fund
IV
+ Sector
Medical Device
+ Company Status
private
+ Investment Status
current
+ Location
Menlo Park, CA
+ Website
https://ajaxhealth.com/
* Allos Therapeutics, Inc.
Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics
+ Year Invested
2002
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Westminster, CO
+ Website
https://sppirx.com/
* Ambit Biosciences Corporation
Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases
+ Year Invested
2001
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
San Diego, CA
+ Website
https://ambitbio.com/
* Antios Therapeutics
Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B-infected patients with a curative combination regimen.
+ Year Invested
2021
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
Atlanta, GA
+ Website
https://antiostherapeutics.com/
* Aragon Pharmaceuticals, Inc.
Oncology drug development company focused on novel therapeutics for prostate and breast cancer
+ Year Invested
2010
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
New Brunswick, NJ
+ Website
https://jnj.com/
* Archimica Cooperatief U.A.
Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry
+ Year Invested
2006
+ Fund
II
+ Sector
Services
+ Company Status
acquired
+ Investment Status
historic
+ Location
Amsterdam, Netherlands
+ Website
euticals.com
* Arcus Biosciences, Inc.
NYSE:RCUS
Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Hayward, CA
+ Website
https://arcusbio.com/
* ARMGO Pharma, Inc.
Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders
+ Year Invested
2006
+ Fund
II
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Tarrytown, NY
+ Website
http://armgo.com/
* ARMO BioSciences, Inc.
NasdaqGS:ARMO
Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Redwood City, CA
+ Website
armobio.com
* Ascendis Pharma A/S
NasdaqGS:ASND
Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Hellerup, Denmark
+ Website
https://ascendispharma.com/
* Aton Pharma, Inc.
Biotechnology company focused on the development of novel treatments for cancer
+ Year Invested
2002
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Tarrytown, NY
+ Website
https://merck.com/
* Atreca, Inc.
NasdaqGS:BCEL
Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Redwood City, CA
+ Website
https://atreca.com/
* Audentes Therapeutics, Inc.
NasdaqGM:BOLD
Biotechnology company developing gene therapy-based treatments in several serious, rare diseases
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
San Francisco, CA
+ Website
https://audentestx.com/
* Auxilium Pharmaceuticals, Inc.
NasdaqGS:AUXL
Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health
+ Year Invested
2003
+ Fund
I
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Chesterbrook, PA
+ Website
auxilium.com
* AVANZA Laboratories, LLC
Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies
+ Year Invested
2009
+ Fund
II
+ Sector
Services
+ Company Status
acquired
+ Investment Status
historic
+ Location
Gaithersburg, MD
+ Website
smithersavanza.com
* AVROBIO, Inc.
NasdaqGS:AVRO
Biotechnology company developing lentiviral-based gene therapies to treat lysosomal storage disorders (LSDs)
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Cambridge, MA
+ Website
https://avrobio.com/
* Axcan Pharma, Inc.
Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders
+ Year Invested
2000
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Quebec, Canada
+ Website
actavis.com
* Barrier Therapeutics, Inc.
Specialty pharmaceutical company focused on development and commercialization of dermatology drugs
+ Year Invested
2002
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Princeton, NJ
+ Website
http://stiefel.com/
* Bicara Therapeutics
Bicara Therapeutics developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.
+ Year Invested
2023
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Cambridge, MA
+ Website
https://bicara.com/
* Bioenvision, Inc.
Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease
+ Year Invested
2002
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
New York, NY
+ Website
genzyme.com
* Biohaven Pharmaceuticals Ltd.
NYSE:BHVN
Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
New Haven, CT
+ Website
https://biohavenpharma.com/
* Biomea Fusion, Inc.
NasdaqGM:BMEA
Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Redwood City, CA
+ Website
https://biomeafusion.com/
* BridgeBio Pharma LLC
NasdaqGS:BBIO
Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Palo Alto, CA
+ Website
https://bridgebio.com/
* CalciMedica, Inc.
CALC
CalciMedica, Inc. is a clinical stage biotechnology company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC (calcium release-activated calcium) channels designed to modulate the immune response and protect against tissue cell injury. The Company is evaluating its lead candidate Auxora, a proprietary intravenous small molecule CRAC channel inhibitor in studies for acute pancreatitis (AP) and acute kidney injury (AKI).
+ Year Invested
2024
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
La Jolla, CA
+ Website
https://calcimedica.com/
* Cardiokine, Inc.
Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases
+ Year Invested
2004
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Philadelphia, PA
+ Website
https://chiesiusa.com/
* Catalent, Inc.
NYSE:CTLT
Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products
+ Year Invested
2007
+ Fund
II
+ Sector
Services
+ Company Status
public
+ Investment Status
historic
+ Location
Somerset, NJ
+ Website
https://catalent.com/
* Cempra, Inc.
NasdaqGS:CEMP
Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria
+ Year Invested
2006
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Chapel Hill, NC
+ Website
cempra.com
* Chimerix, Inc.
NasdaqGM:CMRX
Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Durham, NC
+ Website
https://chimerix.com/
* Cidara Therapeutics, Inc.
NasdaqGM:CDTX
Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments
+ Year Invested
2008
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
San Diego, CA
+ Website
https://cidara.com/
* Clovis Oncology, Inc.
NasdaqGS:CLVS
Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents
+ Year Invested
2011
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Boulder, CO
+ Website
https://clovisoncology.com/
* CollaGenex Pharmaceuticals, Inc.
Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market
+ Year Invested
2001
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Newton, PA
+ Website
https://galderma.com/
* Colorescience, Inc.
Cosmetics company that manufactures and sells mineral-based products
+ Year Invested
2012
+ Fund
I
+ Sector
Consumer
+ Company Status
acquired
+ Investment Status
historic
+ Location
Carlsbad, CA
+ Website
https://colorescience.com/
* COMPASS Pathways
NASDAQGS: CMPS
COMPASS Pathways is a mental health biotechnology company pioneering the development of a new model of psilocybin treatment, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
+ Year Invested
2023
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
London, UK
+ Website
https://compasspathways.com/
* Cynapsus Therapeutics Inc.
NasdaqGM:CYNA
Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease
+ Year Invested
2015
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Toronto, Canada
+ Website
https://cynapsus.ca/
* Cytos Biotechnology AG
SWX:CYTN
Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform
+ Year Invested
2012
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Schlieren, Switzerland
+ Website
cytos.com
* Dermira, Inc.
NasdaqGS:DERM
Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients
+ Year Invested
2014
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Redwood City, CA
+ Website
https://dermira.com/
*
+ Year Invested
2022
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Foster City, CA
+ Website
https://drenbio.com/
* Durata Therapeutics, Inc.
Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses
+ Year Invested
2009
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Chicago, IL
+ Website
duratatherapeutics.com
* EarLens Corporation
Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.
+ Year Invested
2014
+ Fund
III
+ Sector
Medical Device
+ Company Status
private
+ Investment Status
historic
+ Location
Menlo Park, CA
+ Website
https://earlens.com/patients/
* Eidos Therapeutics
NasdaqGS:EIDX
Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
San Francisco, CA
+ Website
https://eidostx.com/
* Elevation Oncology, Inc.
NasdaqGM:ELEV
Elevation Oncology is a clinical-stage oncology company developing targeted therapies for genetically driven cancers. Elevation's lead product candidate, seribantumab, a HER3 monoclonal antibody, is enrolling a Phase 2 registrational trial for NRG1 fusion-driven cancers.
+ Year Invested
2019
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
New York, NY
+ Website
https://elevationoncology.com/
* Esperion Therapeutics, Inc.
NasdaqGM:ESPR
Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases
+ Year Invested
2008
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Ann Arbor, MI
+ Website
https://esperion.com/
* F2G Limited
Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
Manchester, UK
+ Website
https://f2g.com/
*
+ Year Invested
2022
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
Grove City, OH
+ Website
https://forgebiologics.com/
* Garuda Therapeutics, Inc.
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases.
+ Year Invested
2021
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Cambridge, MA
+ Website
garudatx.com
* Global Blood Therapeutics, Inc.
NasdaqGS:GBT
Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
South San Francisco, CA
+ Website
https://gbt.com/
* GTx, Inc.
NasdaqCM:GTXI
Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Memphis, TN
+ Website
gtxinc.com
* Harmony Biosciences, LLC
NasdaqGM:HRMY
Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Plymouth Meeting, PA
+ Website
https://harmonybiosciences.com/
* Ibrutinib Royalty
Anti-cancer drug targeting B-cell malignancies
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
N/A
+ Website
https://imbruvica.com/
* Infinity Pharmaceuticals, Inc.
NasdaqGS:INFI
Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases
+ Year Invested
2012
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Cambridge, MA
+ Website
https://infi.com/
* Intercept Pharmaceuticals, Inc.
NasdaqGS:ICPT
Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry
+ Year Invested
2012
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
New York, NY
+ Website
https://interceptpharma.com/
* Intersect ENT, Inc.
NasdaqGM:XENT
Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions
+ Year Invested
2014
+ Fund
III
+ Sector
Medical Device
+ Company Status
public
+ Investment Status
historic
+ Location
Menlo Park, CA
+ Website
propelopens.com
* LENSAR, Inc.
Leader in next-generation femtosecond laser technology for refractive cataract surgery
+ Year Invested
2008
+ Fund
II
+ Sector
Medical Device
+ Company Status
private
+ Investment Status
historic
+ Location
Orlando, FL
+ Website
https://lensar.com/
* Lombard Medical, Inc.
NasdaqGM:EVAR
Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms
+ Year Invested
2014
+ Fund
III
+ Sector
Medical Device
+ Company Status
public
+ Investment Status
historic
+ Location
Oxfordshire, UK
+ Website
https://lombardmedical.com/
* Loxo Oncology, Inc.
NasdaqGM:LOXO
Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Stamford, CT
+ Website
https://loxooncology.com/
* MAP Pharmaceuticals, Inc.
Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies
+ Year Invested
2003
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Mountain View, CA
+ Website
https://allergan.com/
* Marker Therapeutics, Inc.
NasdaqCM:MRKR
Biotechnology company developing next-generation T cell-based immunotherapies for cancer
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Houston, TX
+ Website
https://markertherapeutics.com/
* MKG LLC
Medical Knowledge Group is comprised of best-in-class medical communications, health care consulting, and data analytics companies. Guided by strategic insight, creative innovation, and medical acumen, MKG companies specialize in distinct service areas within the health care marketing and communications sector.
+ Year Invested
2019
+ Fund
V
+ Sector
Services
+ Company Status
private
+ Investment Status
historic
+ Location
New York, NY
+ Website
https://mkgny.com/
* MEI Pharma, Inc.
NasdaqCM:MEIP
Oncology company focused on the clinical development of novel therapies for cancer
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
San Diego, CA
+ Website
meipharma.com
* Menlo Therapeutics Inc.
NasdaqGS:MNLO
Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
Menlo Park, CA
+ Website
menlotherapeutics.com
* Mindful Health Solutions
+ Year Invested
2024
+ Fund
V
+ Sector
Services
+ Company Status
private
+ Investment Status
current
+ Location
San Francisco, CA
+ Website
https://mindfulhealthsolutions.com/
* Miramar Labs, Inc.
OTC:MRLB
Medical device company focused on developing products for dermatologic medical conditions
+ Year Invested
2011
+ Fund
III
+ Sector
Medical Device
+ Company Status
acquired
+ Investment Status
historic
+ Location
Sunnyvale, CA
+ Website
https://miradry.com/
* Monte Rosa Therapeutics, Inc.
NasdaqGM:GLUE
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles.
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Boston, MA
+ Website
https://monterosatx.com/
* Myogen, Inc.
Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders
+ Year Invested
2001
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Westminster, CO
+ Website
https://gilead.com/
* Nabriva
NasdaqGM:NBRV
Biopharmaceutical company developing new antibiotics to treat infectious diseases
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
King of Prussia, PA
+ Website
https://nabriva.com/
* NextWave Pharmaceuticals, Inc.
Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults
+ Year Invested
2007
+ Fund
II
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Cupertino, CA
+ Website
https://pfizer.com/
* Novazyme Pharmaceuticals, Inc.
Biotechnology company focused on drugs to treat lysosomal storage diseases
+ Year Invested
2000
+ Fund
I
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Princeton, NJ
+ Website
https://sanofigenzyme.com/
* Nuvation Bio, Inc.
NYSE:NUVB
Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.
+ Year Invested
2019
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
New York, NY
+ Website
https://nuvationbio.com/
* ObsEva SA
NasdaqGS:OBSV
Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids
+ Year Invested
2017
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Geneva, Switzerland
+ Website
https://obseva.com/
* Oculex Pharmaceuticals, Inc.
Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions
+ Year Invested
2002
+ Fund
I
+ Sector
Medical Device
+ Company Status
acquired
+ Investment Status
historic
+ Location
Sunnyvale, CA
+ Website
https://allergan.com/
* Paratek Pharmaceuticals, Inc.
NasdaqGM:PRTK
Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering
+ Year Invested
2007
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Boston, MA
+ Website
https://paratekpharma.com/
* PellePharm
Biotechnology company developing topical therapeutics targeting rare dermatological diseases
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
San Francisco, CA
+ Website
https://pellepharm.com/
* Pernix Therapeutics, Inc.
NasdaqGM:PTX
Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products
+ Year Invested
2011
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Houston, TX
+ Website
pernixtx.com
* Pharmaron, Inc.
Provider of research and development services for pharmaceutical and biotechnological industries worldwide
+ Year Invested
2006
+ Fund
II
+ Sector
Services
+ Company Status
private
+ Investment Status
historic
+ Location
Beijing, China
+ Website
https://pharmaron.com/
* Planet Biopharmaceuticals, Inc.
Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy
+ Year Invested
2007
+ Fund
II
+ Sector
Consumer
+ Company Status
acquired
+ Investment Status
historic
+ Location
Liberty, MO
+ Website
areslifesciences.com
* Poseida Therapeutics, Inc.
NasdaqGS:PSTX
Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors.
+ Year Invested
2019
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
San Diego, CA
+ Website
https://poseida.com/
* PowerVision, Inc.
Developer of a fluid-controlled intraocular lens
+ Year Invested
2014
+ Fund
III
+ Sector
Medical Device
+ Company Status
acquired
+ Investment Status
historic
+ Location
Belmont, CA
+ Website
powervisionlens.com
* PreCision Dermatology, Inc.
Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products
+ Year Invested
2012
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Cumberland, RI
+ Website
valeant.com
* Prolacta Bioscience, Inc.
Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
historic
+ Location
City of Industry, CA
+ Website
https://prolacta.com/
* Promentis Pharmaceuticals, Inc.
Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Milwaukee, WI
+ Website
https://promentispharma.com/
* Protagonist Therapeutics, Inc.
NasdaqGM:PTGX
Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Milpitas, CA
+ Website
https://protagonist-inc.com/
* Quintiles Transnational Holdings Inc.
NYSE:Q
Contract pharmaceutical research and sales organization
+ Year Invested
2003
+ Fund
I
+ Sector
Services
+ Company Status
public
+ Investment Status
historic
+ Location
Durham, NC
+ Website
quintiles.com
* Reneo Pharmaceuticals, Inc.
NasdaqGM:RPHM
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria.
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
San Diego, CA
+ Website
https://reneopharma.com
* Roka Bioscience, Inc.
NasdaqGM:ROKA
Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens
+ Year Invested
2011
+ Fund
III
+ Sector
Diagnostics
+ Company Status
public
+ Investment Status
historic
+ Location
Warren, NJ
+ Website
http://rokabio.com/
* Seragon Pharmaceuticals, Inc.
Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
San Diego, CA
+ Website
gene.com
* Sirion Therapeutics, Inc.
Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight
+ Year Invested
2007
+ Fund
II
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Tampa, FL
+ Website
* SkinMedica, Inc.
Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals
+ Year Invested
2004
+ Fund
I
+ Sector
Consumer
+ Company Status
acquired
+ Investment Status
historic
+ Location
Carlsbad, CA
+ Website
https://skinmedica.com/
* Sorrento Therapeutics, Inc.
NasdaqCM:SRNE
Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
San Diego, CA
+ Website
https://sorrentotherapeutics.com/
* Spirox, Inc.
Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction
+ Year Invested
2015
+ Fund
III
+ Sector
Medical Device
+ Company Status
acquired
+ Investment Status
historic
+ Location
Menlo Park, CA
+ Website
spiroxmed.com
* Spruce Biosciences
NasdaqGS: SPRB
Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. Spruce's lead product, tildacerfont, is in late-stage development for classic congenital adrenal hyperplasia (CAH).
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
San Francisco, CA
+ Website
https://sprucebiosciences.com/
* Spyre Therapeutics
NASDAQGS:SYRE
Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience.
+ Year Invested
2023
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Waltham, MA
+ Website
https://spyre.com/
* Syndax Pharmaceuticals, Inc.
NasdaqGS:SNDX
Biotechnology company developing a pipeline of cancer therapies, including a precision oncology asset for genetically-defined acute leukemias.
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
Waltham, MA
+ Website
http://syndax.com/
* Synergy Pharmaceuticals Inc.
NasdaqGS:SGYP
Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders
+ Year Invested
2014
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
New York, NY
+ Website
https://synergypharma.com/
* Syros Pharmaceuticals, Inc.
NasdaqGS:SYRS
Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases
+ Year Invested
2014
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Watertown, MA
+ Website
https://syros.com/
* T2 Biosystems, Inc.
NasdaqGM:TTOO
In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies
+ Year Invested
2011
+ Fund
III
+ Sector
Diagnostics
+ Company Status
public
+ Investment Status
historic
+ Location
Lexington, MA
+ Website
https://t2biosystems.com/
* Talaris Therapeutics, Inc.
NasdaqGM:TALS
Talaris Therapeutics, Inc., formerly Regenerex, is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY.
+ Year Invested
2020
+ Fund
V
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Boston, MA
+ Website
https://talaristx.com/
* Topaz Pharmaceuticals, Inc.
Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.
+ Year Invested
2007
+ Fund
II
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
Horsham, PA
+ Website
https://sanofi.us/
* TransEnterix, Inc.
NYSEMKT:TRXC
Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery
+ Year Invested
2009
+ Fund
III
+ Sector
Medical Device
+ Company Status
public
+ Investment Status
historic
+ Location
Morrisville, NC
+ Website
https://transenterix.com/
* Treeline Biosciences, Inc.
+ Year Invested
2021
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
Stamford, CT
+ Website
https://treelinebiosciences.com/
* TRIA Beauty, Inc.
Medical device company developing and commercializing at-home, light-based skincare products
+ Year Invested
2008
+ Fund
II
+ Sector
Consumer
+ Company Status
private
+ Investment Status
historic
+ Location
Dublin, CA
+ Website
https://triabeauty.com/
* Verona Pharma plc
NasdaqGM:VRNA
UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
London, UK
+ Website
https://veronapharma.com/
* Versartis, Inc.
NasdaqGS:VSAR
Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency
+ Year Invested
2013
+ Fund
III
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Redwood City, CA
+ Website
versartis.com
* ViewRay, Inc.
NasdaqGM:VRAY
Medical device company developing advanced radiation therapy technology for the treatment of cancer
+ Year Invested
2008
+ Fund
II
+ Sector
Medical Device
+ Company Status
public
+ Investment Status
historic
+ Location
Oakwood Village, OH
+ Website
https://viewray.com/
* Viracta Pharmaceuticals, Inc.
NASDAQ: VIRX
Precision oncology company focused on the treatment and prevention of virus-associated cancers
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
current
+ Location
San Diego, CA
+ Website
https://viracta.com/
* VIVUS, Inc.
NasdaqGS:VVUS
Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health
+ Year Invested
2006
+ Fund
II
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Mountain View, CA
+ Website
vivus.com
* Wugen, Inc.
Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in development for acute myelogenous leukemia (AML) and solid tumors. Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).
+ Year Invested
2021
+ Fund
V
+ Sector
Biopharma
+ Company Status
private
+ Investment Status
current
+ Location
St. Louis, MO
+ Website
wugen.com
* Zavante Therapeutics, Inc.
Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital
+ Year Invested
2016
+ Fund
IV
+ Sector
Biopharma
+ Company Status
acquired
+ Investment Status
historic
+ Location
San Diego
+ Website
zavante.com
* ZELTIQ Aesthetics, Inc.
NasdaqGS:ZLTQ
Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction
+ Year Invested
2010
+ Fund
III
+ Sector
Consumer
+ Company Status
acquired
+ Investment Status
historic
+ Location
Pleasanton, CA
+ Website
https://coolsculpting.com/
* Zosano Pharma Corporation
NasdaqCM:ZSAN
Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine
+ Year Invested
2018
+ Fund
IV
+ Sector
Biopharma
+ Company Status
public
+ Investment Status
historic
+ Location
Fremont, CA
+ Website
https://zosanopharma.com/
* Home
* About
* Team
* Portfolio
* News
* Contact
* Terms of Use
© 2024 Aisling Capital. All Rights Reserved. Designed by Shofsky
* 489 5th Avenue 10th Floor New York, NY 10017
* T (212) 651-6380
|
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled